{
    "clinical_study": {
        "@rank": "134777", 
        "brief_summary": {
            "textblock": "Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus\n      ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does\n      not respond to steroid therapy."
        }, 
        "brief_title": "Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease", 
        "completion_date": "June 2003", 
        "condition": "Graft Vs Host Disease", 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Recipient of single allogeneic stem cell    transplant from any donor type\n\n          -  Time post transplant less than 100 days\n\n          -  Received no treatment for GVHD other than steroids\n\n        Exclusion Criteria:\n\n          -  Recipient of second allogeneic stem cell transplant or subsequent lymphocyte product\n             from the donor post transplant\n\n          -  IBMTR index less than A\n\n          -  Received any murine product in the past\n\n          -  Diagnosed with chronic GVHD\n\n          -  Received Atgam later than day 10 post transplant\n\n          -  Change to prophylactic regimen for acute GVHD within 72 hours of randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": "95", 
        "firstreceived_date": "May 6, 2002", 
        "id_info": {
            "nct_alias": "NCT00012077", 
            "nct_id": "NCT00035880", 
            "org_study_id": "ABX-CB-9906"
        }, 
        "intervention": {
            "intervention_name": "ABX-CBL", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "keyword": [
            "Acute graft versus host disease", 
            "Stem Cell Transplantation"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fremont", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94555"
                }, 
                "name": "Abgenix, Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2/Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035880"
        }, 
        "source": "Abgenix", 
        "sponsors": {
            "collaborator": {
                "agency": "Sangstat Medical Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Abgenix", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 1999", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2003"
    }, 
    "geocoordinates": {
        "Abgenix, Inc": "37.548 -121.989"
    }
}